Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D) (NCT07434544) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D)
United States20 participantsStarted 2026-06-01
Plain-language summary
This project will apply a novel non-nutritive sweetener (NNS) dietary assessment tool with measurement of circulating NNS levels in a pediatric population, allowing correlation of NNS exposure to clinically meaningful cardiometabolic health outcomes.
Who can participate
Age range15 Years – 24 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged 15-24 years
✓. Clinical diagnosis of type 1 diabetes, requiring insulin therapy, of ≥ 1 to \< 10 years duration.
✓. Last available HbA1c ≤ 8.5% (obtained by chart review in Children's Wisconsin Diabetes Clinic patients or verbally by individuals not receiving diabetes care at Children's Wisconsin)
✓. Current use of an FDA approved automated insulin delivery (AID) system
✓. Willing to consume a 12 ounce Gatorade G Zero Glacier Cherry drink in less than 10 minutes
✓. Willing and able to give informed consent or have parent or legal guardian provide informed consent if the subject is \< 18 years of age
Exclusion criteria
✕. Any disease other than type 1 diabetes that affects glucose, sex steroid, or fat metabolism such as polycystic ovary syndrome or hypercortisolism
✕. Any medication use that may affect glucose, sex steroid, or fat metabolism such as metformin or glucocorticoids
✕. Half or full sibling already participating in this study
✕. Known cardiovascular disease such as hypertension or atherosclerosis, and/or use of an anti-hypertensive medication
✕. Known hyperlipidemia, defined as LDL ≥ 160 mg/dL, and/or use of lipid-lowering medication, such as statin therapy
What they're measuring
1
Change in "in vivo" endothelial function and vascular stiffness
. Known renal disease or microalbuminuria, and/or use of angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blockers (ARBs) for microalbuminuria
✕. Known diabetic retinopathy or neuropathy
✕. Raynaud's phenomenon or other vascular disease